The latest data point for ABBV's revenue in Q1'26 shows $15.00B USD, marking a 12.43% year-over-year growth and continuing the upward momentum from the previous quarter's $16.62B USD in Q4'25. Over the period from Q2'23 to Q1'26, ABBV's revenue has exhibited a clear recovery and accelerating growth trend, starting from a low of $12.31B USD in Q1'24 after initial declines of around 5% YoY in 2023, then surging to highs of $16.62B USD by Q4'25 with consistent double-digit YoY increases averaging 8-12% in recent quarters. This bar chart highlights a volatile but ultimately positive trajectory, with the overlaid line chart for YoY growth turning positive from Q1'24 onward, indicating robust expansion likely driven by key product performance in the pharmaceutical sector.